Last reviewed · How we verify

DTaP IPV//Hib vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP IPV//Hib vaccine is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children. Also known as: Pentaxim™.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.

At a glance

Generic nameDTaP IPV//Hib vaccine
Also known asPentaxim™
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP IPV//Hib is a pentavalent vaccine containing inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, and Haemophilus influenzae type b conjugate. It works by presenting these antigens to the immune system, triggering both humoral (antibody) and cell-mediated immune responses that provide protection against these five infectious diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP IPV//Hib vaccine

What is DTaP IPV//Hib vaccine?

DTaP IPV//Hib vaccine is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.

How does DTaP IPV//Hib vaccine work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What is DTaP IPV//Hib vaccine used for?

DTaP IPV//Hib vaccine is indicated for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children, Prevention of poliomyelitis in infants and children, Prevention of Haemophilus influenzae type b disease in infants and children.

Who makes DTaP IPV//Hib vaccine?

DTaP IPV//Hib vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is DTaP IPV//Hib vaccine also known as anything else?

DTaP IPV//Hib vaccine is also known as Pentaxim™.

What drug class is DTaP IPV//Hib vaccine in?

DTaP IPV//Hib vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTaP IPV//Hib vaccine in?

DTaP IPV//Hib vaccine is in Phase 3.

What are the side effects of DTaP IPV//Hib vaccine?

Common side effects of DTaP IPV//Hib vaccine include Injection site erythema, Injection site swelling, Injection site pain, Fever, Irritability, Drowsiness.

Related